Life Extension Magazine February 2013
As We See It
Preparing Your Body To Eat
By William Faloon
Dynamic Weight Loss Results
To determine conclusively whether green coffee bean extract has an anti-obesity benefit, scientists set up a randomized, double-blind, placebo-controlled, linear dose, crossover study on humans.1
In a crossover study, participants are cycled through different phases of treatment and placebo. In this case, subjects took a high dose of green coffee bean extract for 6 weeks, a lower dose green coffee bean extract for 6 weeks, and a placebo for 6 weeks in a randomized, double-blind manner. Between phases, there was a 2-week “washout” period, making the entire study 22 weeks long.1
Crossover studies are considered sound, because each person in the test group serves as his or her own control. This improves the chances of getting an accurate result, because it eliminates the possibility of the outcome reflecting a difference between the active and control groups. To ensure the findings were more representative, the investigation enlisted both men and women.
Participants were restricted to those who were classified as obese or pre-obese, because people who have these conditions are subject to obesity’s metabolic effects and find weight loss difficult to achieve.
To further ensure that any effect on weight, body fat or BMI could be solely attributed to the extract, there were no significant changes in dietary calories or in the dietary percentages of carbohydrates, fat, and proteins at any time during the study. There were also no significant changes in exercise. The daily 350 mg capsules of green coffee bean extract were the only intervention, although in a non-study situation, people seeking weight reduction would ideally combine green coffee bean extract with lower calorie consumption and greater physical activity to promote maximum weight loss.
During the high-dose phase, subjects took 350 mg of extract, three times daily. The lower dose phase included 350 mg of extract, taken twice daily.1 The placebo phase involved a 350 mg dose three times daily of an inert capsule containing an inactive substance.1
The striking results were published in January 2012.
Over the 22-week trial, investigators found that all subjects experienced a reduction in body weight, BMI, and body fat during both the high-dose and low-dose phases of the study, but not in the placebo phase!
After 12 weeks of administering 350 mg green coffee bean extract three times a day the scientists found that:1
- Weight decreased by over 17.6 pounds on average—with some subjects losing more than 22.7 pounds!
- BMI decreased by an average of 2.92!
- Body fat percentage decreased by an average 4.44%, with some subjects dropping their body fat percentage by 6.44%!
- Heart rate decreased by a significant average of 2.56 beats per minute!
The substantial anti-obesity impact was clearly reflected in the finding that a remarkable 37% of participants who were assessed as having pre-obesity (25-30 BMI) at the start of the study had their condition reversed to the normal-weight range!1
A study follow-up showed that, contrasting with food-restriction diets, a surprising 87.5% of the test subjects were able to maintain their weight loss after completing the study.1 No side effects were observed.
This and other studies demonstrate the importance of “preparing your body to eat” by taking green coffee bean extract before each meal. The dual effects of reducing after-meal glucose and inducing meaningful weight loss make it a supplement that virtually every aging person should take before eating.
Novel Approach to Reverse Fat Accumulation
Reversing obesity requires attacking it on several fronts, including exercise, diet, and novel interventions such as aggressively lowering glucose and insulin blood levels.
The good news is that scientists have confirmed that green coffee bean extract can inhibit certain obesity-inducing processes. Coffee compounds can reduce body fat,64,66,72 improve lipid profiles,73-75 reduce blood glucose,73,76 and can decrease the absorption of calories!46,66 There are many diet plans that people may be involved with right now. By taking 350 mg of green coffee bean extract before each meal, the fat loss effects may be augmented.1
In the study showing weight loss of 17.6 pounds after 12 weeks, the human subjects were not told to make any significant changes in calorie composition, calorie intake, or exercise habits!1 It is important to understand, however, that people who take the time to participate in weight loss studies want to see results, and may instinctively cut some calories and become more active even when they are told not to.
To optimize this natural approach, overweight and obese individuals should take green coffee bean extract and other nutrients like chromium and green tea extract before each meal.
Save Money While Supporting Research
Every time you purchase a Life Extension® product, you contribute to research aimed at extending healthy human life span. Life Extension® continues to fund a record number of scientific projects, while battling incompetent bureaucrats who seek to suffocate medical innovation.
During our 24th annual winter Super Sale, all Life Extension® formulas are discounted so that members can obtain up-to-date versions at the lowest prices of the year.
Until January 31, 2013, members take advantage of Super Sale discounts to stock up on cutting–edge formulas designed to circumvent the underlying mechanisms of aging…including deadly surplus storage of fat pounds.
For longer life,
- Vinson JA, Burnham BR, Nagendran MV. Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects. Diabetes Metab Syndr Obes. 2012;5:21-7.
- Benn M, Tybjaerg-Hansen A, McCarthy MI, Jensen GB, Grande P, Nordestgaard BG. Nonfasting glucose, ischemic heart disease, and myocardial infarction: a Mendelian randomization study. J Am Coll Cardiol. 2012 Jun 19;59(25):2356-65.
- Bjornholt JV, Erikssen G, Aaser E, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care. 1999 Jan;22(1):45-9.
- Available at: http://www.bls.gov/opub/uscs/1950.pdf. Accessed October 31, 2012.
- Available at: http://www.ers.usda.gov/data-products/food-expenditures.aspx. Accessed October 31, 2012.
- Available at: http://healthland.time.com/2011/11/17/are-smokers-today-more-addicted-than-in-the-past/. Accessed October 31, 2012.
- Available at: http://www.gallup.com/poll/109048/us-smoking-rate-still-coming-down.aspx. Accessed October 31, 2012.
- Available at: http://www.cdc.gov/nchs/fastats/overwt.htm. Accessed October 31, 2012.
- Ceriello A. Mechanisms of tissue damage in the postprandial state. Int J Clin Pract Suppl. 2001 Sep;(123):7-12.
- Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med. 1996 Oct;28(5):419-26.
- Ceriello A. Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia. Am Heart J. 2004 May;147(5):803-7.
- Timmer JR, Hoekstra M, Nijsten MW, et al. Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention. Circulation. 2011 Aug 9;124(6):704-11.
- Norhammar A, Schenck-Gustafsson K. Type 2 diabetes and cardiovascular disease in women. Diabetologia. 2012 Sep 4. [Epub ahead of print]
- Donahue RP, Abbott RD, Reed DM, et al. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes. 1987 Jun;36(6):689-92.
- Fuller JH, Shipley MJ, Rose G, et al: Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall Study. Lancet. 1980 Jun 28; 1(8183):1373-6.
- Haheim LL, Holme I, Hjermann I, et al: Nonfasting serum glucose and the risk of fatal stroke in diabetic and nondiabetic subjects. 18-year follow-up of the Oslo Study. Stroke. 1995 May;26(5):774-7.
- Zeymer U. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes. Int J Cardiol. 2006 Feb 8;107(1):11-20.
- Minatoguchi S, Zhang Z, Bao N, et al. Acarbose reduces myocardial infarct size by preventing postprandial hyperglycemia and hydroxyl radical production and opening mitochondrial KATP channels in rabbits. J Cardiovasc Pharmacol. 2009 Jul;54(1):25-30.
- Frantz S, Calvillo L, Tillmanns J, et al. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose. FASEB J. 2005 Apr;19(6):591-3.
- Parks EJ, Parks EJ. Changes in fat synthesis influenced by dietary macronutrient content. Proc Nutr Soc. 2002 May;61(2):281-6.
- Raffoul JJ; Guo Z; Soofi A; Heydari AR. Caloric restriction and genomic stability. J Nutr Health Aging. 1999 3(2):102-10.
- Martins C, Morgan LM, Robertson MD. Effects of restrained eating behaviour on insulin sensitivity in normal-weight individuals. Physiol Behav. 2009 Mar 23;96(4-5):703-8.
- Heilbronn LK, de Jonge L, Frisard MI, et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA. 2006 Apr 5;295(13):1539-48.
- Heller RF, Heller RF. Hyperinsulinemic obesity and carbohydrate addiction: the missing link is the carbohydrate frequency factor. Med Hypotheses. 1994 May;42(5):307-12.
- Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell. 2008 Oct 3;135(1):61-73.
- Danielsson A, Fagerholm S, Ost A, et al. Short-term overeating induces insulin resistance in fat cells in lean human subjects. Mol Med. 2009 Jul-Aug;15(7-8):228-34.
- Basu R, Chandramouli V, Dicke B, Landau B, Rizza R. Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis. Diabetes. 2005 Jul;54(7):1942-8.
- Kim DH, Perdomo G, Zhang T, et al. FoxO6 integrates insulin signaling with gluconeogenesis in the liver. Diabetes. 2011 Nov;60(11):2763-74.
- de Koning L, Malik VS, Kellogg MD, Rimm EB, Willett WC, Hu FB. Sweetened beverage consumption, incident coronary heart disease, and biomarkers of risk in men. Circulation. 2012 Apr 10;125(14):1735-41, S1.
- Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. J Am Coll Cardiol. 1999 Mar;33(3):612-9.
- D'Elia JN, Salyers AA. Contribution of a neopullulanase, a pullulanase, and an alpha-glucosidase to growth of Bacteroides thetaiotaomicron on starch. J Bacteriol. 1996 Dec;178(24):7173-9.
- Oyama T, Saiki A, Endoh K, et al. Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea. J Atheroscler Thromb. 2008 Jun;15(3):154-9.
- Caton PW, Nayuni NK, Kieswich J, Khan NQ, Yaqoob MM, Corder R. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol. 2010 Apr;205(1):97-106.
- Otto M, Breinholt J, Westergaard N. Metformin inhibits glycogen synthesis and gluconeogenesis in cultured rat hepatocytes. Diabetes Obes Metab. 2003 May;5(3):189-94.
- Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, Ventura MM, Santeusanio F, Brunetti P, Bolli GB. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes. 1994 Jul;43(7):920-8.
- Saxena P, Prakash A, Nigam A. Effect of metformin therapy on 2-h post-glucose insulin levels in patients of polycystic ovarian syndrome. J Hum Reprod Sci. 2010 Sep;3(3):139-42.
- Verma S, Bhanot S, McNeill JH. Metformin decreases plasma insulin levels and systolic blood pressure in spontaneously hypertensive rats. Am J Physiol. 1994 Oct;267(4 Pt 2):H1250-3.
- Isakovic A, Harhaji L, Stevanovic D, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci. 2007 May;64(10):1290-302.
- Xie Y, Wang YL, Yu L, et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol. 2011 Sep;126(3-5):113-20.
- Ben Sahra I, Regazzetti C, Robert G, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011 Jul 1;71(13):4366-72.
- Micic D, Cvijovic G, Trajkovic V, Duntas LH, Polovina S. Metformin: its emerging role in oncology. Hormones (Athens). 2011 Jan-Mar;10(1):5-15.
- Ong KW, Hsu A, Tan BK. Chlorogenic acid stimulates glucose transport in skeletal muscle via AMPK activation: a contributor to the beneficial effects of coffee on diabetes. PLoS One. 2012 7(3):e32718.
- Abidoff MT. Special clinical report on effects of glucose-6-phosphatase on human subjects. Russian Ministry of Health, Moscow, 1999. Unpublished study.
- Nagendran MV. Effect of green coffee bean extract (GCE), High in Chlorogenic Acids, on Glucose Metabolism. Poster presentation number: 45-LB-P. Obesity 2011, the 29th Annual Scientific Meeting of the Obesity Society. Orlando, Florida. October 1-5, 2011.
- Ishikawa A, Yamashita H, Hiemori M, et al. Characterization of inhibitors of postprandial hyperglycemia from the leaves of Nerium indicum. J Nutr Sci Vitaminol (Tokyo). 2007 Apr;53(2):166-73.
- Henry-Vitrac C, Ibarra A, Roller M, Merillon JM, Vitrac X. Contribution of chlorogenic acids to the inhibition of human hepatic glucose-6-phosphatase activity in vitro by Svetol, a standardized decaffeinated green coffee extract. J Agric Food Chem. 2010 Apr 14;58(7):4141-4.
- Andrade-Cetto A, Vazquez RC. Gluconeogenesis inhibition and phytochemical composition of two Cecropia species. J Ethnopharmacol. 2010 Jul 6;130(1):93-7.
- Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes. 1997 Nov;46(11):1786-91.
- Lamson DW, Plaza SM. The safety and efficacy of high-dose chromium. Altern Med Rev. 2002 Jun;7(3):218-35.
- Bahijri SM. Effect of chromium supplementation on glucose tolerance and lipid profile. Saudi Med J. 2000 Jan;21(1):45-50.
- Tsuneki H, Ishizuka M, Terasawa M, Wu JB, Sasaoka T, Kimura I. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. BMC Pharmacol. 2004 Aug 26;4:18.
- Venables MC, Hulston CJ, Cox HR, Jeukendrup AE. Green tea extract ingestion, fat oxidation, and glucose tolerance in healthy humans. Am J Clin Nutr. 2008; 87(3) 778-84.
- Deng ZY, Tao BY, et al. Effect of green tea and black tea on blood glucose, triglycerides, and antioxidants in aged rats. J Agricult Food Chem. 1998 46(10):3875-78.
- Collins QF, Liu HY, Pi J, et al. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5’-AMP-activated protein kinase. J Biol Chem. 2007 Oct 12;282(41):30143-9.
- Cao H, Hininger-Favier I, Kelly MA, et al. Green tea polyphenol extract regulates the expression of genes involved in glucose uptake and insulin signaling in rats fed a high fructose diet. J Agric Food Chem. 2007 Jul 25;55(15):6372-8.
- Ngondi JL, Etoundi BC, Nyangono CB, Mbofung CM, Oben JE. IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation. Lipids Health Dis. 2009 Mar 2;8:7.
- Ngondi JL, Fossouo E, Djiotsa EJ, Oben J. Glycaemic variations after administration of Irvingia gabonensis seeds fractions in normoglycemic rats. Afr J Trad CAM. 2006;3:94-101.
- Adamson I, Okafor C, Abu-Bakare A. A supplement of Dikanut (Irvingia gabonesis) improves treatment of type II diabetics. West Afr J Med. 1990 Apr-Jun;9(2):108-15.
- Zhang Y, Lee ET, Cowan LD, Fabsitz RR, Howard BV. Coffee consumption and the incidence of type 2 diabetes in men and women with normal glucose tolerance: The Strong Heart Study. Nutr Metab Cardiovasc Dis. 2011 Jun;21(6):418-23.
- Johnston KL, Clifford MN, Morgan LM. Coffee acutely modifies gastrointestinal hormone secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. Am J Clin Nutr. 2003 Oct;78(4):728-33.
- Narita Y, Inouye K. Kinetic analysis and mechanism on the inhibition of chlorogenic acid and its components against porcine pancreas alpha-amylase isozymes I and II. J Agric Food Chem. 2009 Oct 14;57(19):9218-25.
- Tunnicliffe JM, Eller LK, Reimer RA, Hittel DS, Shearer J. Chlorogenic acid differentially affects postprandial glucose and glucose-dependent insulinotropic polypeptide response in rats. Appl Physiol Nutr Metab. 2011 Oct;36(5):650-9.
- Loopstra-Masters RC, Liese AD, Haffner SM, Wagenknecht LE, Hanley AJ. Associations between the intake of caffeinated and decaffeinated coffee and measures of insulin sensitivity and beta cell function. Diabetologia. 2011 Feb;54(2):320-8.
- Shimoda H, Seki E, Aitani M. Inhibitory effect of green coffee bean extract on fat accumulation and body weight gain in mice. BMC Complement Altern Med. 2006 Mar 17;6:9.
- Bakuradze T, Boehm N, Janzowski C, et al. Antioxidant-rich coffee reduces DNA damage, elevates glutathione status and contributes to weight control: results from an intervention study. Mol Nutr Food Res. 2011 May;55(5):793-7.
- Thom E. The effect of chlorogenic acid enriched coffee on glucose absorption in healthy volunteers and its effect on body mass when used long-term in overweight and obese people. J Int Med Res. 2007;35(6):900-8.
- Onakpoya I, Terry R, Ernst E. The use of green coffee extract as a weight loss supplement: a systematic review and meta-analysis of randomised clinical trials. Gastroenterol Res Pract. 2011;2011. pii: 382852.
- Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed on April 24, 2012.
- Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006 August 24;355(8):763-78.
- Available at : http://www.oecd.org/dataoecd/1/61/49716427.pdf. Accessed April 24, 2012
- Moriarty J, Branda M, Olsen Kerry, et al. The Effects of incremental costs of smoking and obesity on health care costs among adults: A 7-year longitudinal study. J Occup Environ Med. 2012 March;54(3):286-91.
- Murase T, Misawa K, Minegishi Y, Aoki M, Ominami H, Suzuki Y, Shibuya Y, Hase T. Coffee polyphenols suppress diet-induced body fat accumulation by downregulating SREBP-1c and related molecules in C57BL/6J mice. Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E122-33.
- Li SY, Chang CQ, Ma FY, Yu CL. Modulating effects of chlorogenic acid on lipids and glucose metabolism and expression of hepatic peroxisome proliferator-activated receptor-alpha in golden hamsters fed on high fat diet. Biomed Environ Sci. 2009 Apr;22(2):122-9.
- Superko HR, Bortz W Jr, Williams PT, Albers JJ, Wood PD. Caffeinated and decaffeinated coffee effects on plasma lipoprotein cholesterol, apolipoproteins, and lipase activity: a controlled, randomized trial. Am J Clin Nutr. 1991 Sep;54(3):599-605.
- Cho AS, Jeon SM, Kim MJ, Yeo J, Seo KI, Choi MS, Lee MK. Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice. Food Chem Toxicol. 2010 Mar;48(3):937-43.
- Bidel S, Hu G, Sundvall J, Kaprio J, Tuomilehto J. Effects of coffee consumption on glucose tolerance, serum glucose and insulin levels: a cross-sectional analysis. Horm Metab Res. 2006;38(1):38-43.